Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-02-22
2005-02-22
Stockton, Laura L. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S338000, C514S393000, C514S394000, C546S199000, C546S273100, C548S302100
Reexamination Certificate
active
06858630
ABSTRACT:
Invented are non-peptide TPO mimetics. Also invented is a method of treating thrombocytopenia, in a mammal, including a human, in need thereof which comprises administering to such mammal an effective amount of a selected substituted naphthimidazole derivative.
REFERENCES:
patent: 851444 (1907-04-01), Schulthess
patent: 4411907 (1983-10-01), Toia
patent: 4435417 (1984-03-01), Toja et al.
patent: 193350 (1907-12-01), None
patent: 248383 (1912-06-01), None
patent: WO 9203423 (1992-05-01), None
Beilsteins Handbuch Der Organischen Chemie, Edwards Brothers, Inc., Ann Arbor, Michigan, 1936, p. 528 (Beilstein Citatio 0-25-00-00528).
Duffy Kevin J.
Luengo Juan I.
Price Alan T.
Zhang Lihua
Dustman Wayne I.
Kinzig Charles M.
SmithKline Beecham Corporation
Stockton Laura L.
Venetianer Stephen
LandOfFree
Naphthimidazole derivatives and their use as thrombopoietin... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Naphthimidazole derivatives and their use as thrombopoietin..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Naphthimidazole derivatives and their use as thrombopoietin... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3486743